Research Commons

Human rights responsibilities of pharmaceutical companies in relation to access to medicines

Research Commons

Show simple item record

dc.contributor.author Lee, Joo-Young
dc.contributor.author Hunt, Paul
dc.date.accessioned 2012-10-31T21:19:22Z
dc.date.available 2012-10-31T21:19:22Z
dc.date.issued 2012
dc.identifier.citation Lee, J.-Y. and Hunt, P. (2012), Human rights responsibilities of pharmaceutical companies in relation to access to medicines. The Journal of Law, Medicine & Ethics, 40(2), 220-233. en_NZ
dc.identifier.issn 1748-720X
dc.identifier.uri http://hdl.handle.net/10289/6772
dc.description.abstract Although access to medicines is a vital feature of the right to the highest attainable standard of health (“right to health”), almost two billion people lack access to essential medicines, leading to immense avoidable suffering. While the human rights responsibility to provide access to medicines lies mainly with States, pharmaceutical companies also have human rights responsibilities in relation to access to medicines. This article provides an introduction to these responsibilities. It briefly outlines the new UN Guiding Principles on Business and Human Rights and places the human rights responsibilities of pharmaceutical companies in this context. The authors draw from the work of the first UN Special Rapporteur on the right to the highest attainable standard of health, in particular the Human Rights Guidelines for Pharmaceutical Companies in Relation to Access to Medicines that he presented to the UN General Assembly in 2008, and his UN report on GlaxoSmithKline (GSK). While the Guiding Principles on Business and Human Rights are general human rights standards applicable to all business entities, the Human Rights Guidelines for Pharmaceutical Companies consider the specific human rights responsibilities of one sector (pharmaceutical companies) in relation to one area of activity (access to medicines). The article signals the human rights responsibilities of all pharmaceutical companies, with particular attention to patent-holding pharmaceutical companies. Adopting a right-to-health “lens,” the article discusses GSK and accountability. The authors argue that human rights should shape pharmaceutical companies' policies, and provide standards in relation to which pharmaceutical companies could, and should, be held accountable. They conclude that it is now crucial to devise independent, accessible, transparent, and effective mechanisms to monitor pharmaceutical companies and hold them publicly accountable for their human rights responsibilities. en_NZ
dc.language.iso en
dc.relation.uri http://onlinelibrary.wiley.com/doi/10.1111/j.1748-720X.2012.00660.x/abstract
dc.title Human rights responsibilities of pharmaceutical companies in relation to access to medicines en_NZ
dc.type Journal Article en_NZ
dc.identifier.doi 10.1111/j.1748-720X.2012.00660.x en_NZ


Full-text options:

This item appears in the following Collection(s)

Show simple item record

Search Research Commons


Advanced Search

Browse

Theses

About Research Commons

My Account

Usage Statistics

Share

  • Bookmark and Share